

UNITED THERAPEUTICS CORP

Form 8-K

January 24, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15 (d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 23, 2003

United Therapeutics Corporation

---

(Exact Name of Registrant as Specified in Charter)

Delaware

---

(State or Other  
Jurisdiction of  
Incorporation)

000-26301

---

(Commission  
File Number)

52-1984749

---

(I.R.S. Employer  
Identification Number)

1110 Spring Street  
Silver Spring, MD

---

(Address of Principal Executive Offices)

20910

---

(Zip Code)

Registrant's telephone number, including area code:

(301) 608-9292

---

**Item 5. Other Events.**

On January 23, 2003, United Therapeutics Corporation (the Company ) issued a press release announcing that its wholly owned subsidiary, Unither Pharmaceuticals, had commenced patient enrollment in two identical pivotal clinical trials of OvaRex® MAb (oregovomab), its investigational immunotherapeutic monoclonal antibody being developed for the treatment of stage III/IV advanced ovarian cancer following successful completion of front-line therapy.

**Item 7. Exhibits**

(c) Exhibits

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press release dated January 23, 2003

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: January 24, 2003

By: /s/ Paul Mahon

---

Name: Paul A. Mahon  
Title: SVP and General Counsel

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press release dated January 23, 2003